BridgeBio Oncology Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $121.2M | $73.1M | — | — |
| Operating expenses | $145.8M | $80.9M | — | — |
| Operating income | -$145.8M | -$80.9M | -$41,692 | — |
| Income tax expense | $0 | $0 | — | — |
| Net income | -$134.0M | -$74.3M | -$41,692 | — |
| Balance Sheet | ||||
| Cash and equivalents | $373.7M | $30.9M | — | — |
| Current assets | $432.4M | $158.7M | — | — |
| Total assets | $448.4M | $164.3M | $332,894 | — |
| Current liabilities | $35.0M | $19.6M | $396,463 | — |
| Total liabilities | $37.3M | $19.6M | $396,463 | — |
| Stockholders' equity | $411.1M | -$178.6M | -$115.6M | -$21,877 |
| Cash Flow Statement | ||||
| Cash from operations | -$113.9M | -$55.0M | — | — |
| Depreciation and amortization | $280,000 | $208,000 | — | — |
| Stock-based compensation | $5.9M | $4.4M | — | — |
| Capital expenditure | $606,000 | $49,000 | — | — |
| Free cash flow | -$114.5M | -$55.1M | — | — |
| Impairments | $0 | $0 | — | — |
Shares outstanding 80.1M · Free float 23.9%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.